Bristol-Myers Squibb’s Oncology Portfolio in 4Q17
BMY’s oncology portfolio
Bristol-Myers Squibb’s (BMY) Oncology portfolio includes several key products—Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes more than 47.0% of total revenues for Bristol-Myers Squibb in 4Q17.
The chart below compares the revenues for key oncology products since 1Q16. These drugs reported growth during 4Q17.
Interested in BMY? Don't miss the next report.
Receive e-mail alerts for new research on BMY
Empliciti, the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma, reported revenues of $63.0 million during 4Q17 for 34.0% growth compared to 4Q16.
In fiscal 2017, Empliciti reported revenues of $231.0 million for 54.0% growth compared to revenues of $150.0 million during 2016.
Opdivo, a drug developed in alliance with Ono Pharmaceutical Co., is one of the best-selling drugs from Bristol-Myers Squibb’s portfolio. Opdivo is approved for the treatment of various forms of cancer, including:
- non-small cell lung cancer
- squamous cell carcinoma of head and neck
- classical Hodgkin’s lymphoma
- metastatic melanoma
- renal cell carcinoma
- hepatocellular carcinoma
- dMMR/MSI-H colorectal cancer
- urothelial carcinoma
Opdivo reported revenues of ~$1.4 billion in 4Q17 for 4.0% growth compared to revenues of ~$1.3 billion during 4Q16. For fiscal 2017, Opdivo reported revenues of $4.9 billion for 31.0% growth compared to revenues of $3.8 billion during 2016.
Sprycel, another blockbuster drug in BMY’s oncology portfolio, is approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Sprycel reported revenues of $527.0 million in 4Q17 for 7% growth compared to 4Q16.
For fiscal 2017, Sprycel reported revenues of $2.0 billion for 10.0% growth compared to 2016.
Yervoy is approved for the treatment of melanoma. Yervoy reported revenues of $269.0 million in 4Q17 for 2.0% growth compared to fiscal 2017, Yervoy reported revenues of $1.2 billion, representing 18.0% growth compared to 2016.